Global Sphingolipids Market By Source (Synthetic, Natural), By Product (Ceramide, Sphingomyelin, Sphingosines, Phosphosphingolipids, Glycosphingolipids, Others) By Application (Tissue Development, Cell Recognition, Acting receptor toxin) By End Users (Pharmaceutical companies, Biopharmaceutical companies, Research centers, Others) By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
The sphingolipid group of lipids, which includes ceramide, are found primarily in the cell membranes of plants and animals. They support the structural integrity of cell membranes and play a role in mediating a variety of cellular processes, including those affecting cell growth and differentiation, apoptosis, and intracellular signalling. Ceramide and sphingosine-1-phosphate have recently attracted the attention of numerous studies. Ceramide is produced as a cellular stress response through three metabolic pathways and is stimulated by a variety of events. Ceramide functions as a precursor for numerous other sphingolipids and possesses proapoptotic characteristics. As a ceramide derivative with antiapoptotic and mitogenic properties, sphingosine-1-phosphate plays a crucial role in cardioprotection. As sphingolipid metabolism plays an important part in several pathologies, the pathway of this metabolism has been widely studied. Numerous biochemical routes for synthesis and degradation, as well as the corresponding enzymes, have been effectively identified. This pathway is intricate and entails numerous metabolic processes and cell organelles. These basic sphingolipids have drawn attention in recent years due to their important signalling and regulatory functions in cells. Simple sphingolipid levels have also been extensively studied in recent years due to the proliferation of techniques for measuring them.
In terms of revenue, global sphingolipids market is anticipated to reach US$902.56 Mn by 2030, at a CAGR of 5 % over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Sphingolipids Market Revenue & Forecast, (US$ Million), 2015 – 2030
Type Outlook
Based on the type segment, the global sphingolipids market is segmented into ceramide, sphingomyelin, sphingosines, phosphosphingolipids, glycosphingolipids, others. Sphingolipids come in a variety of forms, each distinguished by the structural and chemical components that are joined to the sphingoid backbone. All other sphingolipids are derivatives of ceramides, the most basic class of sphingolipids, which are composed of sphingosine and fatty acid. Ceramide and sphingosine-1-phosphate have recently attracted the attention of numerous studies. Ceramide is produced as a cellular stress response through three metabolic pathways and is stimulated by a variety of events. Ceramide functions as a precursor for numerous other sphingolipids and possesses proapoptotic characteristics. The ceramide derivative sphingosine-1-phosphate has antiapoptotic and mitogenic properties and plays a significant role in cardioprotection. The prevention and treatment of disorders associated with sedentary lifestyle may be improved by further study on the role of sphingolipids in cellular pathophysiology. Therefore, the development of new sphingolipid types will accelerate the expansion of the global sphingolipids market.
Application Outlook
Based on application, the sphingolipids market is segmented into tissue development, cell recognition, acting receptor toxin. Sphingolipids are typical components of eukaryotic cell membranes that serve as signalling molecules for controlling a variety of cellular activities, such as cell development, survival, and trafficking of immune cells, as well as vascular and epithelial integrity, and inflammation. Recent research has emphasised the critical function of sphingolipids in the control of neuroinflammatory processes. Sphingolipids serve a variety of purposes, including triggering the production of different inflammatory mediators and controlling neuroinflammation by directly influencing central nervous system cells. A growing body of research suggests that sphingolipids play a role in neuroinflammatory illnesses like Alzheimer's and Parkinson's. Neuroinflammatory diseases are characterised by abnormal sphingolipid changes, including an increase in ceramide and a decrease in sphingosine kinase. These patterns, which are seen early in the course of disease development, point to the future potential of sphingolipids as a novel therapeutic and diagnostic target for neuroinflammatory diseases.
Region Outlook
Based on region, North America has the highest share in the sphingolipids market in the year 2021. Due to rising cancer cases, sphingolipids has gained much importance for various novel treatments. Bioactive sphingolipids have been linked to oncogenesis, cancer progression, and drug and radiation resistance in studies. Targeting the components of sphingolipid metabolism therefore seems crucial for the creation of novel treatments or for enhancing. Moreover, the presence of leading market players in United States is contributing to the growth of the sphingolipids market.
Competitive Landscape
The report provides both, qualitative and quantitative research of global sphingolipids market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the key players operating in the global sphingolipids market are listed below:
- CD Bioparticles
- Creative Enzymes
- Croda International Plc
- LARODAN AB
- Lipoid GmbH
- Santa Cruz Biotechnology, Inc
- Thermo Fisher Scientific
- Tokyo Chemical Industry Co., Ltd.
- Other Industry Participants.
Global Sphingolipids Market
By Source
- Synthetic
- Natural
By Product
- Ceramide
- Sphingomyelin
- Sphingosines
- Phosphosphingolipids
- Glycosphingolipids
- Others
By Application
- Tissue Development
- Cell Recognition
- Acting receptor toxin
By End Users
- Pharmaceutical companies
- Biopharmaceutical companies
- Research centers
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1.
Market
Segmentation
1.2.
Years
Considered
1.2.1.
Historic
Years: 2015 - 2020
1.2.2.
Base
Year: 2021
1.2.3.
Forecast
Years: 2022 - 2030
2.
Key
Target Audiences
3.
Research
Methodology
3.1.
Primary
Research
3.1.1.
Research
Questionnaire
3.1.2.
Global
Percentage Breakdown
3.1.3.
Primary
Interviews: Key Opinion Leaders (KOLs)
3.2.
Secondary
Research
3.2.1.
Paid
Databases
3.2.2.
Secondary
Sources
3.3.
Market
Size Estimates
3.3.1.
Top-Down
Approach
3.3.2.
Bottom-Up
Approach
3.4.
Data
Triangulation Methodology
3.5.
Research
Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Sphingolipids Market
6.
Market
Synopsis: Sphingolipids Market
7.
Sphingolipids
Market Analysis: Qualitative Perspective
7.1.
Introduction
7.1.1.
Product
Definition
7.1.2.
Industry
Development
7.2.
Market
Dynamics
7.2.1.
Drivers
7.2.2.
Restraints
7.2.3.
Opportunities
7.2.4.
Challenges
7.3.
Trends
in Sphingolipids Market
7.4.
Market
Determinants Radar Chart
7.5.
Macro-Economic
and Micro-Economic Indicators: Sphingolipids Market
7.6.
Porter’s
Five Force Analysis
7.7.
Impact
of Covid-19 on Sphingolipids Market
8.
Global
Sphingolipids Market Analysis and Forecasts, 2022 - 2030
8.1.
Overview
8.1.1.
Global
Sphingolipids Market Revenue (US$ Mn)
8.2.
Global
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
8.2.1.
Synthetic
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.1.3.
Market
Forecast, 2022 - 2030
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2021
8.2.1.5.1.2. Market Forecast, 2022 - 2030
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2021
8.2.1.5.2.2. Market Forecast, 2022 - 2030
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2021
8.2.1.5.3.2. Market Forecast, 2022 - 2030
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2021
8.2.1.5.4.2. Market Forecast, 2022 - 2030
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2021
8.2.1.5.5.2. Market Forecast, 2022 - 2030
8.2.2.
Natural
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.2.3.
Market
Forecast, 2022 - 2030
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2021
8.2.2.5.1.2. Market Forecast, 2022 - 2030
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2021
8.2.2.5.2.2. Market Forecast, 2022 - 2030
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2021
8.2.2.5.3.2. Market Forecast, 2022 - 2030
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2021
8.2.2.5.4.2. Market Forecast, 2022 - 2030
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2021
8.2.2.5.5.2. Market Forecast, 2022 - 2030
8.3.
Key
Segment for Channeling Investments
8.3.1.
By
Source
9.
Global
Sphingolipids Market Analysis and Forecasts, 2022 - 2030
9.1.
Overview
9.2.
Global
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
9.2.1.
Ceramide
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.1.3.
Market
Forecast, 2022 - 2030
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2021
9.2.1.5.1.2. Market Forecast, 2022 - 2030
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2021
9.2.1.5.2.2. Market Forecast, 2022 - 2030
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2021
9.2.1.5.3.2. Market Forecast, 2022 - 2030
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2021
9.2.1.5.4.2. Market Forecast, 2022 - 2030
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2021
9.2.1.5.5.2. Market Forecast, 2022 - 2030
9.2.2.
Sphingomyelin
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.2.3.
Market
Forecast, 2022 - 2030
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2021
9.2.2.5.1.2. Market Forecast, 2022 - 2030
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2021
9.2.2.5.2.2. Market Forecast, 2022 - 2030
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2021
9.2.2.5.3.2. Market Forecast, 2022 - 2030
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2021
9.2.2.5.4.2. Market Forecast, 2022 - 2030
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2021
9.2.2.5.5.2. Market Forecast, 2022 - 2030
9.2.3.
Sphingosines
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.3.3.
Market
Forecast, 2022 - 2030
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North
America
9.2.3.5.1.1. Market Estimation, 2015 - 2021
9.2.3.5.1.2. Market Forecast, 2022 - 2030
9.2.3.5.2.
Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2021
9.2.3.5.2.2. Market Forecast, 2022 - 2030
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2021
9.2.3.5.3.2. Market Forecast, 2022 - 2030
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2021
9.2.3.5.4.2. Market Forecast, 2022 - 2030
9.2.3.5.5.
Latin
America
9.2.3.5.5.1. Market Estimation, 2015 - 2021
9.2.3.5.5.2. Market Forecast, 2022 - 2030
9.2.4.
Phosphosphingolipids
9.2.4.1.
Definition
9.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.4.3.
Market
Forecast, 2022 - 2030
9.2.4.4.
Compound
Annual Growth Rate (CAGR)
9.2.4.5.
Regional
Bifurcation
9.2.4.5.1.
North
America
9.2.4.5.1.1. Market Estimation, 2015 - 2021
9.2.4.5.1.2. Market Forecast, 2022 - 2030
9.2.4.5.2.
Europe
9.2.4.5.2.1. Market Estimation, 2015 - 2021
9.2.4.5.2.2. Market Forecast, 2022 - 2030
9.2.4.5.3.
Asia
Pacific
9.2.4.5.3.1. Market Estimation, 2015 - 2021
9.2.4.5.3.2. Market Forecast, 2022 - 2030
9.2.4.5.4.
Middle
East and Africa
9.2.4.5.4.1. Market Estimation, 2015 - 2021
9.2.4.5.4.2. Market Forecast, 2022 - 2030
9.2.4.5.5.
Latin
America
9.2.4.5.5.1. Market Estimation, 2015 - 2021
9.2.4.5.5.2. Market Forecast, 2022 - 2030
9.2.5.
Glycosphingolipids
9.2.5.1.
Definition
9.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.5.3.
Market
Forecast, 2022 - 2030
9.2.5.4.
Compound
Annual Growth Rate (CAGR)
9.2.5.5.
Regional
Bifurcation
9.2.5.5.1.
North
America
9.2.5.5.1.1. Market Estimation, 2015 - 2021
9.2.5.5.1.2. Market Forecast, 2022 - 2030
9.2.5.5.2.
Europe
9.2.5.5.2.1. Market Estimation, 2015 - 2021
9.2.5.5.2.2. Market Forecast, 2022 - 2030
9.2.5.5.3.
Asia
Pacific
9.2.5.5.3.1. Market Estimation, 2015 - 2021
9.2.5.5.3.2. Market Forecast, 2022 - 2030
9.2.5.5.4.
Middle
East and Africa
9.2.5.5.4.1. Market Estimation, 2015 - 2021
9.2.5.5.4.2. Market Forecast, 2022 - 2030
9.2.5.5.5.
Latin
America
9.2.5.5.5.1. Market Estimation, 2015 - 2021
9.2.5.5.5.2. Market Forecast, 2022 - 2030
9.2.6.
Others
9.2.6.1.
Definition
9.2.6.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.6.3.
Market
Forecast, 2022 - 2030
9.2.6.4.
Compound
Annual Growth Rate (CAGR)
9.2.6.5.
Regional
Bifurcation
9.2.6.5.1.
North
America
9.2.6.5.1.1. Market Estimation, 2015 - 2021
9.2.6.5.1.2. Market Forecast, 2022 - 2030
9.2.6.5.2.
Europe
9.2.6.5.2.1. Market Estimation, 2015 - 2021
9.2.6.5.2.2. Market Forecast, 2022 - 2030
9.2.6.5.3.
Asia
Pacific
9.2.6.5.3.1. Market Estimation, 2015 - 2021
9.2.6.5.3.2. Market Forecast, 2022 - 2030
9.2.6.5.4.
Middle
East and Africa
9.2.6.5.4.1. Market Estimation, 2015 - 2021
9.2.6.5.4.2. Market Forecast, 2022 - 2030
9.2.6.5.5.
Latin
America
9.2.6.5.5.1. Market Estimation, 2015 - 2021
9.2.6.5.5.2. Market Forecast, 2022 - 2030
9.3.
Key
Segment for Channeling Investments
9.3.1.
By
Product
10. Global Sphingolipids Market Analysis and
Forecasts, 2022 - 2030
10.1. Overview
10.2. Global Sphingolipids Market Revenue (US$ Mn)
and Forecasts, By Application
10.2.1. Tissue Development
10.2.1.1.
Definition
10.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.1.3.
Market
Forecast, 2022 - 2030
10.2.1.4.
Compound
Annual Growth Rate (CAGR)
10.2.1.5.
Regional
Bifurcation
10.2.1.5.1.
North
America
10.2.1.5.1.1. Market Estimation, 2015 - 2021
10.2.1.5.1.2. Market Forecast, 2022 - 2030
10.2.1.5.2.
Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2021
10.2.1.5.2.2. Market Forecast, 2022 - 2030
10.2.1.5.3.
Asia
Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2021
10.2.1.5.3.2. Market Forecast, 2022 - 2030
10.2.1.5.4.
Middle
East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2021
10.2.1.5.4.2. Market Forecast, 2022 - 2030
10.2.1.5.5.
Latin
America
10.2.1.5.5.1. Market Estimation, 2015 - 2021
10.2.1.5.5.2. Market Forecast, 2022 - 2030
10.2.2. Cell Recognition
10.2.2.1.
Definition
10.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.2.3.
Market
Forecast, 2022 - 2030
10.2.2.4.
Compound
Annual Growth Rate (CAGR)
10.2.2.5.
Regional
Bifurcation
10.2.2.5.1.
North
America
10.2.2.5.1.1. Market Estimation, 2015 - 2021
10.2.2.5.1.2. Market Forecast, 2022 - 2030
10.2.2.5.2.
Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2021
10.2.2.5.2.2. Market Forecast, 2022 - 2030
10.2.2.5.3.
Asia
Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2021
10.2.2.5.3.2. Market Forecast, 2022 - 2030
10.2.2.5.4.
Middle
East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2021
10.2.2.5.4.2. Market Forecast, 2022 - 2030
10.2.2.5.5.
Latin
America
10.2.2.5.5.1. Market Estimation, 2015 - 2021
10.2.2.5.5.2. Market Forecast, 2022 - 2030
10.2.3. Acting receptor toxin
10.2.3.1.
Definition
10.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.3.3.
Market
Forecast, 2022 - 2030
10.2.3.4.
Compound
Annual Growth Rate (CAGR)
10.2.3.5.
Regional
Bifurcation
10.2.3.5.1.
North
America
10.2.3.5.1.1. Market Estimation, 2015 - 2021
10.2.3.5.1.2. Market Forecast, 2022 - 2030
10.2.3.5.2.
Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2021
10.2.3.5.2.2. Market Forecast, 2022 - 2030
10.2.3.5.3.
Asia
Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2021
10.2.3.5.3.2. Market Forecast, 2022 - 2030
10.2.3.5.4.
Middle
East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2021
10.2.3.5.4.2. Market Forecast, 2022 - 2030
10.2.3.5.5.
Latin
America
10.2.3.5.5.1. Market Estimation, 2015 - 2021
10.2.3.5.5.2. Market Forecast, 2022 - 2030
10.3. Key Segment for Channeling Investments
10.3.1. By Application
11. Global Sphingolipids Market Analysis and
Forecasts, 2022 - 2030
11.1. Overview
11.2. Global Sphingolipids Market Revenue (US$ Mn)
and Forecasts, By End Users
11.2.1. Pharmaceutical companies
11.2.1.1.
Definition
11.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.1.3.
Market
Forecast, 2022 - 2030
11.2.1.4.
Compound
Annual Growth Rate (CAGR)
11.2.1.5.
Regional
Bifurcation
11.2.1.5.1.
North
America
11.2.1.5.1.1. Market Estimation, 2015 - 2021
11.2.1.5.1.2. Market Forecast, 2022 - 2030
11.2.1.5.2.
Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2021
11.2.1.5.2.2. Market Forecast, 2022 - 2030
11.2.1.5.3.
Asia
Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2021
11.2.1.5.3.2. Market Forecast, 2022 - 2030
11.2.1.5.4.
Middle
East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2021
11.2.1.5.4.2. Market Forecast, 2022 - 2030
11.2.1.5.5.
Latin
America
11.2.1.5.5.1. Market Estimation, 2015 - 2021
11.2.1.5.5.2. Market Forecast, 2022 - 2030
11.2.2. Biopharmaceutical companies
11.2.2.1.
Definition
11.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.2.3.
Market
Forecast, 2022 - 2030
11.2.2.4.
Compound
Annual Growth Rate (CAGR)
11.2.2.5.
Regional
Bifurcation
11.2.2.5.1.
North
America
11.2.2.5.1.1. Market Estimation, 2015 - 2021
11.2.2.5.1.2. Market Forecast, 2022 - 2030
11.2.2.5.2.
Europe
11.2.2.5.2.1. Market Estimation, 2015 - 2021
11.2.2.5.2.2. Market Forecast, 2022 - 2030
11.2.2.5.3.
Asia
Pacific
11.2.2.5.3.1. Market Estimation, 2015 - 2021
11.2.2.5.3.2. Market Forecast, 2022 - 2030
11.2.2.5.4.
Middle
East and Africa
11.2.2.5.4.1. Market Estimation, 2015 - 2021
11.2.2.5.4.2. Market Forecast, 2022 - 2030
11.2.2.5.5.
Latin
America
11.2.2.5.5.1. Market Estimation, 2015 - 2021
11.2.2.5.5.2. Market Forecast, 2022 - 2030
11.2.3. Research centers
11.2.3.1.
Definition
11.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.3.3.
Market
Forecast, 2022 - 2030
11.2.3.4.
Compound
Annual Growth Rate (CAGR)
11.2.3.5.
Regional
Bifurcation
11.2.3.5.1.
North
America
11.2.3.5.1.1. Market Estimation, 2015 - 2021
11.2.3.5.1.2. Market Forecast, 2022 - 2030
11.2.3.5.2.
Europe
11.2.3.5.2.1. Market Estimation, 2015 - 2021
11.2.3.5.2.2. Market Forecast, 2022 - 2030
11.2.3.5.3.
Asia
Pacific
11.2.3.5.3.1. Market Estimation, 2015 - 2021
11.2.3.5.3.2. Market Forecast, 2022 - 2030
11.2.3.5.4.
Middle
East and Africa
11.2.3.5.4.1. Market Estimation, 2015 - 2021
11.2.3.5.4.2. Market Forecast, 2022 - 2030
11.2.3.5.5.
Latin
America
11.2.3.5.5.1. Market Estimation, 2015 - 2021
11.2.3.5.5.2. Market Forecast, 2022 - 2030
11.2.4. Others
11.2.4.1.
Definition
11.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.4.3.
Market
Forecast, 2022 - 2030
11.2.4.4.
Compound
Annual Growth Rate (CAGR)
11.2.4.5.
Regional
Bifurcation
11.2.4.5.1.
North
America
11.2.4.5.1.1. Market Estimation, 2015 - 2021
11.2.4.5.1.2. Market Forecast, 2022 - 2030
11.2.4.5.2.
Europe
11.2.4.5.2.1. Market Estimation, 2015 - 2021
11.2.4.5.2.2. Market Forecast, 2022 - 2030
11.2.4.5.3.
Asia
Pacific
11.2.4.5.3.1. Market Estimation, 2015 - 2021
11.2.4.5.3.2. Market Forecast, 2022 - 2030
11.2.4.5.4.
Middle
East and Africa
11.2.4.5.4.1. Market Estimation, 2015 - 2021
11.2.4.5.4.2. Market Forecast, 2022 - 2030
11.2.4.5.5.
Latin
America
11.2.4.5.5.1. Market Estimation, 2015 - 2021
11.2.4.5.5.2. Market Forecast, 2022 - 2030
11.3. Key Segment for Channeling Investments
11.3.1. By End Users
12. North America Sphingolipids Market Analysis
and Forecasts, 2022 - 2030
12.1. Overview
12.1.1. North America Sphingolipids Market Revenue
(US$ Mn)
12.2. North America Sphingolipids Market Revenue
(US$ Mn) and Forecasts, By Source
12.2.1. Synthetic
12.2.2. Natural
12.3. North America Sphingolipids Market Revenue
(US$ Mn) and Forecasts, By Product
12.3.1. Ceramide
12.3.2. Sphingomyelin
12.3.3. Sphingosines
12.3.4. Phosphosphingolipids
12.3.5. Glycosphingolipids
12.3.6. Others
12.4. North America Sphingolipids Market Revenue
(US$ Mn) and Forecasts, By Application
12.4.1. Tissue Development
12.4.2. Cell Recognition
12.4.3. Acting receptor toxin
12.5. North America Sphingolipids Market Revenue
(US$ Mn) and Forecasts, By End Users
12.5.1. Pharmaceutical companies
12.5.2. Biopharmaceutical companies
12.5.3. Research centers
12.5.4. Others
12.6. North America Sphingolipids Market Revenue
(US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1.
U.S
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
12.6.1.1.1.
Synthetic
12.6.1.1.2.
Natural
12.6.1.2.
U.S
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
12.6.1.2.1.
Ceramide
12.6.1.2.2.
Sphingomyelin
12.6.1.2.3.
Sphingosines
12.6.1.2.4.
Phosphosphingolipids
12.6.1.2.5.
Glycosphingolipids
12.6.1.2.6.
Others
12.6.1.3.
U.S
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
12.6.1.3.1.
Tissue
Development
12.6.1.3.2.
Cell Recognition
12.6.1.3.3.
Acting
receptor toxin
12.6.1.4.
U.S
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.1.4.1.
Pharmaceutical
companies
12.6.1.4.2.
Biopharmaceutical
companies
12.6.1.4.3.
Research
centers
12.6.1.4.4.
Others
12.6.2. Canada
12.6.2.1.
Canada
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
12.6.2.1.1.
Synthetic
12.6.2.1.2.
Natural
12.6.2.2.
Canada
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
12.6.2.2.1.
Ceramide
12.6.2.2.2.
Sphingomyelin
12.6.2.2.3.
Sphingosines
12.6.2.2.4.
Phosphosphingolipids
12.6.2.2.5.
Glycosphingolipids
12.6.2.2.6.
Others
12.6.2.3.
Canada Sphingolipids
Market Revenue (US$ Mn) and Forecasts, By Application
12.6.2.3.1.
Tissue
Development
12.6.2.3.2.
Cell
Recognition
12.6.2.3.3.
Acting
receptor toxin
12.6.2.4.
Canada
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.2.4.1.
Pharmaceutical
companies
12.6.2.4.2.
Biopharmaceutical
companies
12.6.2.4.3.
Research
centers
12.6.2.4.4.
Others
12.6.3. Mexico
12.6.3.1.
Mexico
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
12.6.3.1.1.
Synthetic
12.6.3.1.2.
Natural
12.6.3.2.
Mexico
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
12.6.3.2.1.
Ceramide
12.6.3.2.2.
Sphingomyelin
12.6.3.2.3.
Sphingosines
12.6.3.2.4.
Phosphosphingolipids
12.6.3.2.5.
Glycosphingolipids
12.6.3.2.6.
Others
12.6.3.3.
Mexico
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
12.6.3.3.1.
Tissue
Development
12.6.3.3.2.
Cell
Recognition
12.6.3.3.3.
Acting
receptor toxin
12.6.3.4.
Mexico
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.3.4.1.
Pharmaceutical
companies
12.6.3.4.2.
Biopharmaceutical
companies
12.6.3.4.3.
Research
centers
12.6.3.4.4.
Others
12.6.4. Rest of North America
12.6.4.1.
Rest of
North America Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
12.6.4.1.1.
Synthetic
12.6.4.1.2.
Natural
12.6.4.2.
Rest of
North America Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
12.6.4.2.1.
Ceramide
12.6.4.2.2.
Sphingomyelin
12.6.4.2.3.
Sphingosines
12.6.4.2.4.
Phosphosphingolipids
12.6.4.2.5.
Glycosphingolipids
12.6.4.2.6.
Others
12.6.4.3.
Rest of
North America Sphingolipids Market Revenue (US$ Mn) and Forecasts, By
Application
12.6.4.3.1.
Tissue
Development
12.6.4.3.2.
Cell
Recognition
12.6.4.3.3.
Acting
receptor toxin
12.6.4.4.
Rest of
North America Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.4.4.1.
Pharmaceutical
companies
12.6.4.4.2.
Biopharmaceutical
companies
12.6.4.4.3.
Research
centers
12.6.4.4.4.
Others
12.7. Key Segment for Channeling Investments
12.7.1. By Country
12.7.2. By Source
12.7.3. By Product
12.7.4. By Application
12.7.5. By End Users
13. Europe Sphingolipids Market Analysis and
Forecasts, 2022 - 2030
13.1. Overview
13.1.1. Europe Sphingolipids Market Revenue (US$ Mn)
13.2. Europe Sphingolipids Market Revenue (US$ Mn)
and Forecasts, By Source
13.2.1. Synthetic
13.2.2. Natural
13.3. Europe Sphingolipids Market Revenue (US$ Mn)
and Forecasts, By Product
13.3.1. Ceramide
13.3.2. Sphingomyelin
13.3.3. Sphingosines
13.3.4. Phosphosphingolipids
13.3.5. Glycosphingolipids
13.3.6. Others
13.4. Europe Sphingolipids Market Revenue (US$ Mn)
and Forecasts, By Application
13.4.1. Tissue Development
13.4.2. Cell Recognition
13.4.3. Acting receptor toxin
13.5. Europe Sphingolipids Market Revenue (US$ Mn)
and Forecasts, By End Users
13.5.1. Pharmaceutical companies
13.5.2. Biopharmaceutical companies
13.5.3. Research centers
13.5.4. Others
13.6. Europe Sphingolipids Market Revenue (US$ Mn)
and Forecasts, By Country
13.6.1. France
13.6.1.1.
France
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
13.6.1.1.1.
Synthetic
13.6.1.1.2.
Natural
13.6.1.2.
France
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
13.6.1.2.1.
Ceramide
13.6.1.2.2.
Sphingomyelin
13.6.1.2.3.
Sphingosines
13.6.1.2.4.
Phosphosphingolipids
13.6.1.2.5.
Glycosphingolipids
13.6.1.2.6.
Others
13.6.1.3.
France
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
13.6.1.3.1.
Tissue
Development
13.6.1.3.2.
Cell
Recognition
13.6.1.3.3.
Acting
receptor toxin
13.6.1.4.
France
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.1.4.1.
Pharmaceutical
companies
13.6.1.4.2.
Biopharmaceutical
companies
13.6.1.4.3.
Research
centers
13.6.1.4.4.
Others
13.6.2. The UK
13.6.2.1.
The UK
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
13.6.2.1.1.
Synthetic
13.6.2.1.2.
Natural
13.6.2.2.
The UK
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
13.6.2.2.1.
Ceramide
13.6.2.2.2.
Sphingomyelin
13.6.2.2.3.
Sphingosines
13.6.2.2.4.
Phosphosphingolipids
13.6.2.2.5.
Glycosphingolipids
13.6.2.2.6.
Others
13.6.2.3.
The UK
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
13.6.2.3.1.
Tissue
Development
13.6.2.3.2.
Cell
Recognition
13.6.2.3.3.
Acting
receptor toxin
13.6.2.4.
The UK
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.2.4.1.
Pharmaceutical
companies
13.6.2.4.2.
Biopharmaceutical
companies
13.6.2.4.3.
Research
centers
13.6.2.4.4.
Others
13.6.3. Spain
13.6.3.1.
Spain
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
13.6.3.1.1.
Synthetic
13.6.3.1.2.
Natural
13.6.3.2.
Spain
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
13.6.3.2.1.
Ceramide
13.6.3.2.2.
Sphingomyelin
13.6.3.2.3.
Sphingosines
13.6.3.2.4.
Phosphosphingolipids
13.6.3.2.5.
Glycosphingolipids
13.6.3.2.6.
Others
13.6.3.3.
Spain
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
13.6.3.3.1.
Tissue
Development
13.6.3.3.2.
Cell
Recognition
13.6.3.3.3.
Acting
receptor toxin
13.6.3.4.
Spain
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.3.4.1.
Pharmaceutical
companies
13.6.3.4.2.
Biopharmaceutical
companies
13.6.3.4.3.
Research
centers
13.6.3.4.4.
Others
13.6.4. Germany
13.6.4.1.
Germany
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
13.6.4.1.1.
Synthetic
13.6.4.1.2.
Natural
13.6.4.2.
Germany
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
13.6.4.2.1.
Ceramide
13.6.4.2.2.
Sphingomyelin
13.6.4.2.3.
Sphingosines
13.6.4.2.4.
Phosphosphingolipids
13.6.4.2.5.
Glycosphingolipids
13.6.4.2.6.
Others
13.6.4.3.
Germany
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
13.6.4.3.1.
Tissue
Development
13.6.4.3.2.
Cell
Recognition
13.6.4.3.3.
Acting
receptor toxin
13.6.4.4.
Germany
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.4.4.1.
Pharmaceutical
companies
13.6.4.4.2.
Biopharmaceutical
companies
13.6.4.4.3.
Research
centers
13.6.4.4.4.
Others
13.6.5. Italy
13.6.5.1.
Italy
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
13.6.5.1.1.
Synthetic
13.6.5.1.2.
Natural
13.6.5.2.
Italy
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
13.6.5.2.1.
Ceramide
13.6.5.2.2.
Sphingomyelin
13.6.5.2.3.
Sphingosines
13.6.5.2.4.
Phosphosphingolipids
13.6.5.2.5.
Glycosphingolipids
13.6.5.2.6.
Others
13.6.5.3.
Italy
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
13.6.5.3.1.
Tissue
Development
13.6.5.3.2.
Cell
Recognition
13.6.5.3.3.
Acting
receptor toxin
13.6.5.4.
Italy
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.5.4.1.
Pharmaceutical
companies
13.6.5.4.2.
Biopharmaceutical
companies
13.6.5.4.3.
Research
centers
13.6.5.4.4.
Others
13.6.6. Nordic Countries
13.6.6.1.
Nordic
Countries Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
13.6.6.1.1.
Synthetic
13.6.6.1.2.
Natural
13.6.6.2.
Nordic
Countries Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
13.6.6.2.1.
Ceramide
13.6.6.2.2.
Sphingomyelin
13.6.6.2.3.
Sphingosines
13.6.6.2.4.
Phosphosphingolipids
13.6.6.2.5.
Glycosphingolipids
13.6.6.2.6.
Others
13.6.6.3.
Nordic
Countries Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
13.6.6.3.1.
Tissue
Development
13.6.6.3.2.
Cell
Recognition
13.6.6.3.3.
Acting
receptor toxin
13.6.6.4.
Nordic
Countries Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.6.4.1.
Pharmaceutical
companies
13.6.6.4.2.
Biopharmaceutical
companies
13.6.6.4.3.
Research
centers
13.6.6.4.4.
Others
13.6.6.5.
Nordic
Countries Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Country
13.6.6.5.1.
Denmark
13.6.6.5.2.
Finland
13.6.6.5.3.
Iceland
13.6.6.5.4.
Sweden
13.6.6.5.5.
Norway
13.6.7. Benelux Union
13.6.7.1.
Benelux
Union Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
13.6.7.1.1.
Synthetic
13.6.7.1.2.
Natural
13.6.7.2.
Benelux
Union Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
13.6.7.2.1.
Ceramide
13.6.7.2.2.
Sphingomyelin
13.6.7.2.3.
Sphingosines
13.6.7.2.4.
Phosphosphingolipids
13.6.7.2.5.
Glycosphingolipids
13.6.7.2.6.
Others
13.6.7.3.
Benelux
Union Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
13.6.7.3.1.
Tissue
Development
13.6.7.3.2.
Cell
Recognition
13.6.7.3.3.
Acting
receptor toxin
13.6.7.4.
Benelux
Union Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.7.4.1.
Pharmaceutical
companies
13.6.7.4.2.
Biopharmaceutical
companies
13.6.7.4.3.
Research
centers
13.6.7.4.4.
Others
13.6.7.5.
Benelux
Union Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Country
13.6.7.5.1.
Belgium
13.6.7.5.2.
The
Netherlands
13.6.7.5.3.
Luxembourg
13.6.8. Rest of Europe
13.6.8.1.
Rest of
Europe Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
13.6.8.1.1.
Synthetic
13.6.8.1.2.
Natural
13.6.8.2.
Rest of
Europe Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
13.6.8.2.1.
Ceramide
13.6.8.2.2.
Sphingomyelin
13.6.8.2.3.
Sphingosines
13.6.8.2.4.
Phosphosphingolipids
13.6.8.2.5.
Glycosphingolipids
13.6.8.2.6.
Others
13.6.8.3.
Rest of
Europe Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
13.6.8.3.1.
Tissue
Development
13.6.8.3.2.
Cell
Recognition
13.6.8.3.3.
Acting
receptor toxin
13.6.8.4.
Rest of
Europe Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.8.4.1.
Pharmaceutical
companies
13.6.8.4.2.
Biopharmaceutical
companies
13.6.8.4.3.
Research
centers
13.6.8.4.4.
Others
13.7. Key Segment for Channeling Investments
13.7.1. By Country
13.7.2. By Source
13.7.3. By Product
13.7.4. By Application
13.7.5. By End Users
14. Asia Pacific Sphingolipids Market Analysis
and Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Asia Pacific Sphingolipids Market Revenue
(US$ Mn)
14.2. Asia Pacific Sphingolipids Market Revenue
(US$ Mn) and Forecasts, By Source
14.2.1. Synthetic
14.2.2. Natural
14.3. Asia Pacific Sphingolipids Market Revenue
(US$ Mn) and Forecasts, By Product
14.3.1. Ceramide
14.3.2. Sphingomyelin
14.3.3. Sphingosines
14.3.4. Phosphosphingolipids
14.3.5. Glycosphingolipids
14.3.6. Others
14.4. Asia Pacific Sphingolipids Market Revenue
(US$ Mn) and Forecasts, By Application
14.4.1. Tissue Development
14.4.2. Cell Recognition
14.4.3. Acting receptor toxin
14.5. Asia Pacific Sphingolipids Market Revenue
(US$ Mn) and Forecasts, By End Users
14.5.1. Pharmaceutical companies
14.5.2. Biopharmaceutical companies
14.5.3. Research centers
14.5.4. Others
14.6. Asia Pacific Sphingolipids Market Revenue
(US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1.
China
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
14.6.1.1.1.
Synthetic
14.6.1.1.2.
Natural
14.6.1.2.
China
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
14.6.1.2.1.
Ceramide
14.6.1.2.2.
Sphingomyelin
14.6.1.2.3.
Sphingosines
14.6.1.2.4.
Phosphosphingolipids
14.6.1.2.5.
Glycosphingolipids
14.6.1.2.6.
Others
14.6.1.3.
China
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
14.6.1.3.1.
Tissue
Development
14.6.1.3.2.
Cell
Recognition
14.6.1.3.3.
Acting
receptor toxin
14.6.1.4.
China
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.1.4.1.
Pharmaceutical
companies
14.6.1.4.2.
Biopharmaceutical
companies
14.6.1.4.3.
Research
centers
14.6.1.4.4.
Others
14.6.2. Japan
14.6.2.1.
Japan
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
14.6.2.1.1.
Synthetic
14.6.2.1.2.
Natural
14.6.2.2.
Japan
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
14.6.2.2.1.
Ceramide
14.6.2.2.2.
Sphingomyelin
14.6.2.2.3.
Sphingosines
14.6.2.2.4.
Phosphosphingolipids
14.6.2.2.5.
Glycosphingolipids
14.6.2.2.6.
Others
14.6.2.3.
Japan
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
14.6.2.3.1.
Tissue
Development
14.6.2.3.2.
Cell
Recognition
14.6.2.3.3.
Acting
receptor toxin
14.6.2.4.
Japan
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.2.4.1.
Pharmaceutical
companies
14.6.2.4.2.
Biopharmaceutical
companies
14.6.2.4.3.
Research
centers
14.6.2.4.4.
Others
14.6.3. India
14.6.3.1.
India
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
14.6.3.1.1.
Synthetic
14.6.3.1.2.
Natural
14.6.3.2.
India
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
14.6.3.2.1.
Ceramide
14.6.3.2.2.
Sphingomyelin
14.6.3.2.3.
Sphingosines
14.6.3.2.4.
Phosphosphingolipids
14.6.3.2.5.
Glycosphingolipids
14.6.3.2.6.
Others
14.6.3.3.
India
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
14.6.3.3.1.
Tissue
Development
14.6.3.3.2.
Cell
Recognition
14.6.3.3.3.
Acting
receptor toxin
14.6.3.4.
India
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.3.4.1.
Pharmaceutical
companies
14.6.3.4.2.
Biopharmaceutical
companies
14.6.3.4.3.
Research
centers
14.6.3.4.4.
Others
14.6.4. New Zealand
14.6.4.1.
New
Zealand Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
14.6.4.1.1.
Synthetic
14.6.4.1.2.
Natural
14.6.4.2.
New
Zealand Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
14.6.4.2.1.
Ceramide
14.6.4.2.2.
Sphingomyelin
14.6.4.2.3.
Sphingosines
14.6.4.2.4.
Phosphosphingolipids
14.6.4.2.5.
Glycosphingolipids
14.6.4.2.6.
Others
14.6.4.3.
New
Zealand Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
14.6.4.3.1.
Tissue
Development
14.6.4.3.2.
Cell
Recognition
14.6.4.3.3.
Acting
receptor toxin
14.6.4.4.
New
Zealand Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.4.4.1.
Pharmaceutical
companies
14.6.4.4.2.
Biopharmaceutical
companies
14.6.4.4.3.
Research
centers
14.6.4.4.4.
Others
14.6.5. Australia
14.6.5.1.
Australia
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
14.6.5.1.1.
Synthetic
14.6.5.1.2.
Natural
14.6.5.2.
Australia
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
14.6.5.2.1.
Ceramide
14.6.5.2.2.
Sphingomyelin
14.6.5.2.3.
Sphingosines
14.6.5.2.4.
Phosphosphingolipids
14.6.5.2.5.
Glycosphingolipids
14.6.5.2.6.
Others
14.6.5.3.
Australia
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
14.6.5.3.1.
Tissue
Development
14.6.5.3.2.
Cell
Recognition
14.6.5.3.3.
Acting
receptor toxin
14.6.5.4.
Australia
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.5.4.1.
Pharmaceutical
companies
14.6.5.4.2.
Biopharmaceutical
companies
14.6.5.4.3.
Research
centers
14.6.5.4.4.
Others
14.6.6. South Korea
14.6.6.1.
South
Korea Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
14.6.6.1.1.
Synthetic
14.6.6.1.2.
Natural
14.6.6.2.
South
Korea Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
14.6.6.2.1.
Ceramide
14.6.6.2.2.
Sphingomyelin
14.6.6.2.3.
Sphingosines
14.6.6.2.4.
Phosphosphingolipids
14.6.6.2.5.
Glycosphingolipids
14.6.6.2.6.
Others
14.6.6.3.
South
Korea Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
14.6.6.3.1.
Tissue
Development
14.6.6.3.2.
Cell
Recognition
14.6.6.3.3.
Acting
receptor toxin
14.6.6.4.
South
Korea Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.6.4.1.
Pharmaceutical
companies
14.6.6.4.2.
Biopharmaceutical
companies
14.6.6.4.3.
Research
centers
14.6.6.4.4.
Others
14.6.7. Southeast Asia
14.6.7.1.
Southeast
Asia Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
14.6.7.1.1.
Synthetic
14.6.7.1.2.
Natural
14.6.7.2.
Southeast
Asia Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
14.6.7.2.1.
Ceramide
14.6.7.2.2.
Sphingomyelin
14.6.7.2.3.
Sphingosines
14.6.7.2.4.
Phosphosphingolipids
14.6.7.2.5.
Glycosphingolipids
14.6.7.2.6.
Others
14.6.7.3.
Southeast
Asia Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
14.6.7.3.1.
Tissue
Development
14.6.7.3.2.
Cell
Recognition
14.6.7.3.3.
Acting
receptor toxin
14.6.7.4.
Southeast
Asia Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.7.4.1.
Pharmaceutical
companies
14.6.7.4.2.
Biopharmaceutical
companies
14.6.7.4.3.
Research
centers
14.6.7.4.4.
Others
14.6.7.5.
Southeast
Asia Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Country
14.6.7.5.1.
Indonesia
14.6.7.5.2.
Thailand
14.6.7.5.3.
Malaysia
14.6.7.5.4.
Singapore
14.6.7.5.5.
Rest of
Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1.
Rest of
Asia Pacific Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
14.6.8.1.1.
Synthetic
14.6.8.1.2.
Natural
14.6.8.2.
Rest of
Asia Pacific Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
14.6.8.2.1.
Ceramide
14.6.8.2.2.
Sphingomyelin
14.6.8.2.3.
Sphingosines
14.6.8.2.4.
Phosphosphingolipids
14.6.8.2.5.
Glycosphingolipids
14.6.8.2.6.
Others
14.6.8.3.
Rest of
Asia Pacific Sphingolipids Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.8.3.1.
Tissue
Development
14.6.8.3.2.
Cell
Recognition
14.6.8.3.3.
Acting
receptor toxin
14.6.8.4.
Rest of
Asia Pacific Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.8.4.1.
Pharmaceutical
companies
14.6.8.4.2.
Biopharmaceutical
companies
14.6.8.4.3.
Research
centers
14.6.8.4.4.
Others
14.7. Key Segment for Channeling Investments
14.7.1. By Country
14.7.2. By Source
14.7.3. By Product
14.7.4. By Application
14.7.5. By End Users
15. Middle East and Africa Sphingolipids Market
Analysis and Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Middle East and Africa Sphingolipids Market
Revenue (US$ Mn)
15.2. Middle East and Africa Sphingolipids Market
Revenue (US$ Mn) and Forecasts, By Source
15.2.1. Synthetic
15.2.2. Natural
15.3. Middle East and Africa Sphingolipids Market
Revenue (US$ Mn) and Forecasts, By Product
15.3.1. Ceramide
15.3.2. Sphingomyelin
15.3.3. Sphingosines
15.3.4. Phosphosphingolipids
15.3.5. Glycosphingolipids
15.3.6. Others
15.4. Middle East and Africa Sphingolipids Market
Revenue (US$ Mn) and Forecasts, By Application
15.4.1. Tissue Development
15.4.2. Cell Recognition
15.4.3. Acting receptor toxin
15.5. Middle East and Africa Sphingolipids Market Revenue
(US$ Mn) and Forecasts, By End Users
15.5.1. Pharmaceutical companies
15.5.2. Biopharmaceutical companies
15.5.3. Research centers
15.5.4. Others
15.6. Middle East and Africa Sphingolipids Market
Revenue (US$ Mn) and Forecasts, By Country
15.6.1. Saudi Arabia
15.6.1.1.
Saudi
Arabia Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
15.6.1.1.1.
Synthetic
15.6.1.1.2.
Natural
15.6.1.2.
Saudi
Arabia Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
15.6.1.2.1.
Ceramide
15.6.1.2.2.
Sphingomyelin
15.6.1.2.3.
Sphingosines
15.6.1.2.4.
Phosphosphingolipids
15.6.1.2.5.
Glycosphingolipids
15.6.1.2.6.
Others
15.6.1.3.
Saudi
Arabia Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
15.6.1.3.1.
Tissue
Development
15.6.1.3.2.
Cell
Recognition
15.6.1.3.3.
Acting
receptor toxin
15.6.1.4.
Saudi
Arabia Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.1.4.1.
Pharmaceutical
companies
15.6.1.4.2.
Biopharmaceutical
companies
15.6.1.4.3.
Research
centers
15.6.1.4.4.
Others
15.6.2. UAE
15.6.2.1.
UAE
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
15.6.2.1.1.
Synthetic
15.6.2.1.2.
Natural
15.6.2.2.
UAE
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
15.6.2.2.1.
Ceramide
15.6.2.2.2.
Sphingomyelin
15.6.2.2.3.
Sphingosines
15.6.2.2.4.
Phosphosphingolipids
15.6.2.2.5.
Glycosphingolipids
15.6.2.2.6.
Others
15.6.2.3.
UAE
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
15.6.2.3.1.
Tissue
Development
15.6.2.3.2.
Cell
Recognition
15.6.2.3.3.
Acting
receptor toxin
15.6.2.4.
UAE
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.2.4.1.
Pharmaceutical
companies
15.6.2.4.2.
Biopharmaceutical
companies
15.6.2.4.3.
Research
centers
15.6.2.4.4.
Others
15.6.3. Egypt
15.6.3.1.
Egypt
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
15.6.3.1.1.
Synthetic
15.6.3.1.2.
Natural
15.6.3.2.
Egypt
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
15.6.3.2.1.
Ceramide
15.6.3.2.2.
Sphingomyelin
15.6.3.2.3.
Sphingosines
15.6.3.2.4.
Phosphosphingolipids
15.6.3.2.5.
Glycosphingolipids
15.6.3.2.6.
Others
15.6.3.3.
Egypt
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
15.6.3.3.1.
Tissue
Development
15.6.3.3.2.
Cell
Recognition
15.6.3.3.3.
Acting
receptor toxin
15.6.3.4.
Egypt
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.3.4.1.
Pharmaceutical
companies
15.6.3.4.2.
Biopharmaceutical
companies
15.6.3.4.3.
Research
centers
15.6.3.4.4.
Others
15.6.4. Kuwait
15.6.4.1.
Kuwait
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
15.6.4.1.1.
Synthetic
15.6.4.1.2.
Natural
15.6.4.2.
Kuwait
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
15.6.4.2.1.
Ceramide
15.6.4.2.2.
Sphingomyelin
15.6.4.2.3.
Sphingosines
15.6.4.2.4.
Phosphosphingolipids
15.6.4.2.5.
Glycosphingolipids
15.6.4.2.6.
Others
15.6.4.3.
Kuwait
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
15.6.4.3.1.
Tissue
Development
15.6.4.3.2.
Cell
Recognition
15.6.4.3.3.
Acting
receptor toxin
15.6.4.4.
Kuwait
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.4.4.1.
Pharmaceutical
companies
15.6.4.4.2.
Biopharmaceutical
companies
15.6.4.4.3.
Research
centers
15.6.4.4.4.
Others
15.6.5. South Africa
15.6.5.1.
South
Africa Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
15.6.5.1.1.
Synthetic
15.6.5.1.2.
Natural
15.6.5.2.
South
Africa Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
15.6.5.2.1.
Ceramide
15.6.5.2.2.
Sphingomyelin
15.6.5.2.3.
Sphingosines
15.6.5.2.4.
Phosphosphingolipids
15.6.5.2.5.
Glycosphingolipids
15.6.5.2.6.
Others
15.6.5.3.
South
Africa Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
15.6.5.3.1.
Tissue
Development
15.6.5.3.2.
Cell
Recognition
15.6.5.3.3.
Acting
receptor toxin
15.6.5.4.
South
Africa Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.5.4.1.
Pharmaceutical
companies
15.6.5.4.2.
Biopharmaceutical
companies
15.6.5.4.3.
Research
centers
15.6.5.4.4.
Others
15.6.6. Rest of Middle East & Africa
15.6.6.1.
Rest of
Middle East & Africa Sphingolipids Market Revenue (US$ Mn) and Forecasts,
By Source
15.6.6.1.1.
Synthetic
15.6.6.1.2.
Natural
15.6.6.2.
Rest of
Middle East & Africa Sphingolipids Market Revenue (US$ Mn) and Forecasts,
By Product
15.6.6.2.1.
Ceramide
15.6.6.2.2.
Sphingomyelin
15.6.6.2.3.
Sphingosines
15.6.6.2.4.
Phosphosphingolipids
15.6.6.2.5.
Glycosphingolipids
15.6.6.2.6.
Others
15.6.6.3.
Rest of
Middle East & Africa Sphingolipids Market Revenue (US$ Mn) and Forecasts,
By Application
15.6.6.3.1.
Tissue
Development
15.6.6.3.2.
Cell
Recognition
15.6.6.3.3.
Acting
receptor toxin
15.6.6.4.
Rest of
Middle East & Africa Sphingolipids Market Revenue (US$ Mn) and Forecasts,
By End Users
15.6.6.4.1.
Pharmaceutical
companies
15.6.6.4.2.
Biopharmaceutical
companies
15.6.6.4.3.
Research
centers
15.6.6.4.4.
Others
15.7. Key Segment for Channeling Investments
15.7.1. By Country
15.7.2. By Source
15.7.3. By Product
15.7.4. By Application
15.7.5. By End Users
16. Latin America Sphingolipids Market Analysis
and Forecasts, 2022 - 2030
16.1. Overview
16.1.1. Latin America Sphingolipids Market Revenue
(US$ Mn)
16.2. Latin America Sphingolipids Market Revenue
(US$ Mn) and Forecasts, By Source
16.2.1. Synthetic
16.2.2. Natural
16.3. Latin America Sphingolipids Market Revenue
(US$ Mn) and Forecasts, By Product
16.3.1. Ceramide
16.3.2. Sphingomyelin
16.3.3. Sphingosines
16.3.4. Phosphosphingolipids
16.3.5. Glycosphingolipids
16.3.6. Others
16.4. Latin America Sphingolipids Market Revenue
(US$ Mn) and Forecasts, By Application
16.4.1. Tissue Development
16.4.2. Cell Recognition
16.4.3. Acting receptor toxin
16.5. Latin America Sphingolipids Market Revenue
(US$ Mn) and Forecasts, By End Users
16.5.1. Pharmaceutical companies
16.5.2. Biopharmaceutical companies
16.5.3. Research centers
16.5.4. Others
16.6. Latin America Sphingolipids Market Revenue
(US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1.
Brazil
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
16.6.1.1.1.
Synthetic
16.6.1.1.2.
Natural
16.6.1.2.
Brazil
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
16.6.1.2.1.
Ceramide
16.6.1.2.2.
Sphingomyelin
16.6.1.2.3.
Sphingosines
16.6.1.2.4.
Phosphosphingolipids
16.6.1.2.5.
Glycosphingolipids
16.6.1.2.6.
Others
16.6.1.3.
Brazil
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
16.6.1.3.1.
Tissue
Development
16.6.1.3.2.
Cell
Recognition
16.6.1.3.3.
Acting
receptor toxin
16.6.1.4.
Brazil
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.1.4.1.
Pharmaceutical
companies
16.6.1.4.2.
Biopharmaceutical
companies
16.6.1.4.3.
Research
centers
16.6.1.4.4.
Others
16.6.2. Argentina
16.6.2.1.
Argentina
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
16.6.2.1.1.
Synthetic
16.6.2.1.2.
Natural
16.6.2.2.
Argentina
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
16.6.2.2.1.
Ceramide
16.6.2.2.2.
Sphingomyelin
16.6.2.2.3.
Sphingosines
16.6.2.2.4.
Phosphosphingolipids
16.6.2.2.5.
Glycosphingolipids
16.6.2.2.6.
Others
16.6.2.3.
Argentina
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Application
16.6.2.3.1.
Tissue
Development
16.6.2.3.2.
Cell
Recognition
16.6.2.3.3.
Acting
receptor toxin
16.6.2.4.
Argentina
Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.2.4.1.
Pharmaceutical
companies
16.6.2.4.2.
Biopharmaceutical
companies
16.6.2.4.3.
Research
centers
16.6.2.4.4.
Others
16.6.3. Rest of Latin America
16.6.3.1.
Rest of
Latin America Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Source
16.6.3.1.1.
Synthetic
16.6.3.1.2.
Natural
16.6.3.2.
Rest of
Latin America Sphingolipids Market Revenue (US$ Mn) and Forecasts, By Product
16.6.3.2.1.
Ceramide
16.6.3.2.2.
Sphingomyelin
16.6.3.2.3.
Sphingosines
16.6.3.2.4.
Phosphosphingolipids
16.6.3.2.5.
Glycosphingolipids
16.6.3.2.6.
Others
16.6.3.3.
Rest of
Latin America Sphingolipids Market Revenue (US$ Mn) and Forecasts, By
Application
16.6.3.3.1.
Tissue
Development
16.6.3.3.2.
Cell
Recognition
16.6.3.3.3.
Acting
receptor toxin
16.6.3.4.
Rest of
Latin America Sphingolipids Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.3.4.1.
Pharmaceutical
companies
16.6.3.4.2.
Biopharmaceutical
companies
16.6.3.4.3.
Research
centers
16.6.3.4.4.
Others
16.7. Key Segment for Channeling Investments
16.7.1. By Country
16.7.2. By Source
16.7.3. By Product
16.7.4. By Application
16.7.5. By End Users
17. Competitive Benchmarking
17.1. Brand Benchmarking
17.2. Market Share Analysis, 2021
17.3. Global Presence and Growth Strategies
17.3.1. Mergers and Acquisitions
17.3.2. Product Launches
17.3.3. Investments Trends
17.3.4. R&D Initiatives
18. Player Profiles
18.1. CD Bioparticles
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. Creative Enzymes.
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. Croda International Plc.
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. LARODAN AB
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. Lipoid GmbH
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. Santa Cruz Biotechnology, Inc
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. Thermo Fisher Scientific
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. Tokyo Chemical Industry Co., Ltd.
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7.
Business
Strategies
18.9. Other Market Participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.